8.09
前日終値:
$7.58
開ける:
$7.79
24時間の取引高:
7.20M
Relative Volume:
1.81
時価総額:
$711.62M
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-1.4763
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
+17.76%
1か月 パフォーマンス:
+11.59%
6か月 パフォーマンス:
-45.04%
1年 パフォーマンス:
-64.75%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
NTLA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
8.09 | 711.62M | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2025-03-05 | 開始されました | H.C. Wainwright | Buy |
2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-04-13 | 開始されました | Canaccord Genuity | Buy |
2023-03-21 | 開始されました | Bernstein | Outperform |
2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2022-09-21 | 開始されました | JP Morgan | Overweight |
2022-09-01 | 開始されました | Citigroup | Sell |
2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
2022-06-16 | 開始されました | BofA Securities | Buy |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-02-18 | 開始されました | William Blair | Outperform |
2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
2022-01-31 | 開始されました | Cowen | Outperform |
2022-01-07 | 開始されました | Piper Sandler | Overweight |
2021-10-05 | 開始されました | Guggenheim | Buy |
2021-09-24 | 開始されました | Stifel | Buy |
2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
2021-06-11 | 開始されました | H.C. Wainwright | Buy |
2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-27 | 開始されました | Truist | Buy |
2020-10-14 | 開始されました | Wells Fargo | Overweight |
2020-09-18 | 開始されました | Goldman | Buy |
2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
2019-07-09 | 開始されました | Robert W. Baird | Outperform |
2019-06-10 | 開始されました | ROTH Capital | Neutral |
2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
2018-10-29 | 開始されました | Credit Suisse | Neutral |
2018-09-21 | 開始されました | Raymond James | Mkt Perform |
2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
2017-11-01 | 繰り返されました | Jefferies | Buy |
2017-06-22 | 再開されました | Jefferies | Buy |
2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com
Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks
Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
Intellia commercial position in question after safety event. says Goldman - TipRanks
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concerns | NTLA Stock News - GuruFocus
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus
Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria
Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech
Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus
H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga
Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India
Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada
Intellia stock tumbles on safety concerns - Investing.com
Intellia stock down on safety concern for gene editing drug - Seeking Alpha
Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):